Oncolytic measles virus strains in the treatment of gliomas

Cory Allen, Georgia Paraskevakou, Chunsheng Liu, Ianko D. Iankov, Pavlos Msaouel, Paula Zollman, Evanthia Galanis

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Background: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. Objective: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. Methods: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. Results/conclusions: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.

Original languageEnglish (US)
Pages (from-to)213-220
Number of pages8
JournalExpert Opinion on Biological Therapy
Issue number2
StatePublished - Feb 2008


  • Brain tumor
  • Engineering
  • Measles virus
  • Retargeting
  • Virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Oncolytic measles virus strains in the treatment of gliomas'. Together they form a unique fingerprint.

Cite this